HomeInsights52 Week Low Stocks

Orchid Pharma Ltd 52 Week Low

Orchid Pharma Ltd 52 Week Low

stocks purchased

₹ 1.1 Cr

Volume transacted

stocks purchased

7.9 K

stocks traded

Last Updated time: 05 Nov 14:09 PM

Image

Orchid Pharma Ltd

NSE: ORCHPHARMA

YEARLOW

487.2

Last updated on: Nov 04, 2024

Key Highlights

  • The 52 Week Low of Orchid Pharma Ltd is ₹ 487.2 as of 04 Nov 24.

Company Fundamentals for Orchid Pharma Ltd

No data available

Market price Over Time

1M

1Y

3Y

5Y

Monitoring Orchid Pharma Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPriceleft
04 Nov 20241394.75
01 Nov 20241449.3
31 Oct 20241456.2
30 Oct 20241390.7
29 Oct 20241309.25
28 Oct 20241283.3
25 Oct 20241255.45
24 Oct 20241325.25
23 Oct 20241280.85
22 Oct 20241237.9

Asset Value vs Market Value of Orchid Pharma Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Historical Revenue of Orchid Pharma Ltd

No data available

* All values are in crore

Historical Net Profit of Orchid Pharma Ltd

No data available

* All values are in crore

Orchid Pharma Ltd News Hub

News

Orchid Pharma announces board meeting date

Orchid Pharma will hold a meeting of the Board of Directors of the Company on 12 August 20...

Read more

10 Aug 202412:49

News

Orchid Pharma to conduct AGM

Orchid Pharma announced that the Annual General Meeting (AGM) of the company will be held ...

Read more

18 Jul 202420:35

News

Orchid Pharma partners with Cipla for pan-India distribution of Cefepime-Enmetazobactam

Cefepime-Enmetazobactam has been approved for the treatment of complicated urinary tract i...

Read more

29 Jun 202410:08

News

Orchid Pharma partners with Cipla to launch antibiotic drug - Cefepime-Enmetazobactam in India

Orchid Pharma announced the launch of its new drug - Cefepime-Enmetazobactam, which has be...

Read more

28 Jun 202419:23

News

Orchid Pharma receives DCGI approval for Enmetazobactam

Orchid Pharma has received Drugs Controller General of India (DCGI) approval for the manuf...

Read more

06 Jun 202413:06

News

Orchid Pharma gains on DCGI nod for new antibiotic drug combination

DCGI has also granted permission to manufacture and market finished dosage form (FDF) of C...

Read more

06 Jun 202412:38

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

FAQs for 52 Week Low of Orchid Pharma Ltd

Why is it important to track the 52-week low of Orchid Pharma Ltd stocks?

Investors should monitor the 52-week low of Orchid Pharma Ltd stocks regularly to stay informed about significant price changes and assess the stock's performance over time. Frequent monitoring will help traders identify trends and make timely decisions.

What factors can lead to Orchid Pharma Ltd stocks hitting a 52-week low?

Factors leading to Orchid Pharma Ltd stocks hitting a 52-week low may include poor fiscal results, negative industry trends, macroeconomic issues, or management changes. Other factors such as market volatility and broader economic downturns can also contribute to a 52-week low.

Should investors buy Orchid Pharma Ltd stocks when they hit a 52-week low?

Buying Orchid Pharma Ltd stocks at a 52-week low can offer a potential bargain, however, it is crucial to evaluate the reasons behind the stock price drop and ensure there is no underlying fundamental issue. Investors should consider the company's long-term prospects before making a buying decision.

How often should investors monitor the 52-week low of Orchid Pharma Ltd stocks?

Investors should monitor the 52-week low of Orchid Pharma Ltd stocks regularly to stay informed about significant price changes and assess the stock's performance over time, which will help them identify trends and make timely decisions.

How can an investor assess the risk of buying Orchid Pharma Ltd stock at their 52-week low?

An investor can analyze the reasons for the Orchid Pharma Ltd stock price drop, evaluate the company’s fundamentals, and consider market conditions. Investors should also review the stock’s historical performance and any potential recovery indicators.

Should investors consider the overall market trend when evaluating Orchid Pharma Ltd stocks at their 52-week low?

Certainly, considering the overall market trend when evaluating Orchid Pharma Ltd stocks at their 52-week low is significant as it provides context for the stock’s performance and potential future movements. A declining market trend may influence Orchid Pharma Ltd stock performance, impacting the timing and potential of the investment.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*